David Portnoy, Chairman and Co-CEO, has demonstrated a consistent buying pattern in shares of Cryo-Cell International (CCEL), with no recorded sales across 40 transactions totaling $1.8 million in purchases. His recent activity shows a concentrated focus on CCEL, with two notable acquisitions on January 7, 2026, valued at $583,500 and $194,500, marking his largest single-day investments. Prior to these, Portnoy executed a series of smaller but frequent buys throughout November 2025, ranging from $1,156 to $22,000 per transaction, with particularly active days on November 10–12 ($10,217.62, $8,404.80, and $5,716) and November 17–21 ($26,617.77 across five trades). Earlier purchases in September 2025 were more substantial, including multiple five-figure transactions such as $48,554 on September 10 and $28,762.54 on September 16. The absence of any sell-side activity suggests a long-term accumulation strategy in CCEL, with Portnoy increasing his stake methodically—first through larger, intermittent purchases in late 2025 before ramping up frequency and volume into early 2026. The transactions, all coded as open-market or derivative purchases, reflect a singular focus on one company rather than diversification across multiple holdings.
AI-assisted summary